Current status and challenges in HER2 IHC assessment: scoring survey results in Japan
This study highlighted the current status of HER2 expression scoring by IHC for breast cancer among pathologists in Japan. These findings underscore the challenges in HER2 IHC scoring cases and emphasize the need for improved standardization and training, especially in the evolving landscape of HER2-targeted therapies.
Authors
- Shinobu Masuda (ORCID: https://orcid.org/0000-0002-0361-8071)
- Rie Horii (ORCID: https://orcid.org/0000-0002-4227-2739)
- Naoko Honma (ORCID: https://orcid.org/0000-0002-0400-0791)
- Tomo Osako
- Amiko Hayashi
- Hitoshi Tsuda (ORCID: https://orcid.org/0000-0003-3457-4224)
- Masayuki Yoshida (ORCID: https://orcid.org/0000-0002-7198-8357)
- Takashi Sakatani (ORCID: https://orcid.org/0000-0001-5959-3451)
- Ana Richelia Jara‐Lazaro
Institutions
- Nihon University (JP)
- Toho University (JP)
- Yokohama City University Medical Center (JP)
- Roche (Japan) (JP)
- Saitama Cancer Center (JP)
- Nippon Medical School Hospital (JP)
- Tokyo National Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- National Defense Medical College (JP)
- Nippon Medical School (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1007/s10549-024-07532-2
- Citations
- 6
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.70